Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134 USD | +1.89% | -1.85% | +7.99% |
Apr. 22 | John Chevedden Submits a Shareholder Proposal to DexCom | CI |
Apr. 22 | Myra K. Young Submits a Shareholder Proposal to DexCom | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 67% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 79.74 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.99% | 53.07B | B- | ||
-2.25% | 187B | C+ | ||
-1.32% | 108B | C | ||
-3.92% | 67.71B | A | ||
+15.74% | 47.36B | B- | ||
+6.01% | 39.73B | B+ | ||
+10.81% | 28.56B | A- | ||
+2.34% | 26.55B | B | ||
+15.97% | 25.13B | A- | ||
-0.16% | 24.97B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.